Microba Life Sciences (ASX:MAP) accelerates cancer program with new therapeutic leads
Microba Life Sciences (MAP) identifies three therapeutic leads for its immuno-oncology program…
Change | ||
S&P/ASX Sm. Ords. | |||
All Ordinaries | |||
S&P/ASX 100 |
RKN | RECKON LIMITED | $1.30 | 48.6% |
PYR | PAYRIGHT LIMITED | 19.5¢ | 30.0% |
FIN | FIN RESOURCES LIMITED | 2.6¢ | 23.8% |
PO3 | PURIFLOH LIMITED | 26.5¢ | 20.9% |
DTR | DATELINE RESOURCES LIMITED | 10.0¢ | 16.7% |
OAK | OAKRIDGE INTERNATIONAL LIMITED | 11.0¢ | 15.4% |
Date | Announcement | File | Views |
---|---|---|---|
10/05/2022 | Change in substantial holding | 799.72KB | 186 |
09/05/2022 | Microba Appoints Senior US Sales Lead | 153.49KB | 122 |
05/05/2022 | Price Sensitive PS Microba Accelerates Cancer Program | 200.39KB | 160 |
29/04/2022 | International Conference Presentation | 1.68MB | 425 |
13/04/2022 | Microba CSO presents to US industry conference | 2.84MB | 1.6K |
13/04/2022 | Change of Director's Interest Notice - Prof Ian Frazer | 205.78KB | 309 |
13/04/2022 | Change of Director's Interest Notice - Pasquale Rombola | 204.45KB | 140 |
07/04/2022 | ShareCafe Small Cap Hidden Gems Presentation | 129.05KB | 478 |